Dorsomorphin (Compound C): Precision AMPK Inhibition for Advanced Research

Principle and Setup: Targeting the AMPK and BMP/Smad Signaling Pathways

Dorsomorphin (Compound C) stands at the forefront of cell signaling research, acting as a potent, reversible, and highly selective ATP-competitive AMPK inhibitor (Ki = 109 nM). Developed to dissect complex cellular networks, Dorsomorphin distinguishes itself by dual action—suppressing not only the AMP-activated protein kinase (AMPK) pathway but also serving as a highly effective BMP/Smad signaling inhibitor. Its selectivity profile ensures minimal off-target effects, as evidenced by negligible activity against kinases such as PKA, PKC, and JAK3.

Mechanistically, Dorsomorphin blocks AMPK-mediated phosphorylation events, including >80% inhibition of acetyl-CoA carboxylase (ACC) phosphorylation, leading to profound effects on downstream autophagic processes and metabolic flux. Simultaneously, it inhibits BMP4-induced SMAD 1/5/8 phosphorylation (IC₅₀ = 0.47 μM), making it invaluable for studies in developmental biology, stem cell fate, and iron metabolism modulation. APExBIO supplies Dorsomorphin as a solid, with optimal solubility in DMSO at concentrations ≥8.49 mg/mL using gentle warming and ultrasonic treatment. Solutions should be prepared fresh and used promptly, as long-term storage is not recommended.

Step-by-Step Experimental Workflow and Protocol Enhancements

1. Compound Preparation

• Weigh Dorsomorphin and dissolve in DMSO to achieve a stock concentration of at least 8.5 mg/mL. Apply gentle warming and ultrasonic agitation to facilitate dissolution. Avoid water or ethanol, as the product is insoluble in these solvents.
• For cell culture, dilute the DMSO stock into culture media to achieve a working concentration of 4–40 μM, ensuring final DMSO concentrations remain below 0.1% to preserve cell viability.

2. Inhibition of AMPK Activity in Hepatocytes and Cancer Cell Lines

• Seed hepatocytes or HeLa cells at appropriate density. Allow cells to adhere overnight.
• Treat cells with Dorsomorphin at 10–20 μM for 1–4 hours for robust inhibition of AMPK signaling. For extended autophagy or metabolic studies, longer treatment durations (up to 24 hours) are feasible, but verify cell viability regularly.
• Harvest cells and assess ACC phosphorylation via Western blot. Expect ~80% reduction in p-ACC relative to control, confirming pathway suppression.

3. BMP4-Induced SMAD Phosphorylation Inhibition

• Pre-treat stem cells or differentiation models with Dorsomorphin (2–10 μM) for 30–60 minutes prior to BMP4 stimulation.
• After BMP4 exposure, collect lysates and probe for phosphorylated SMAD 1/5/8 by immunoblotting or immunofluorescence. Dorsomorphin at 0.5–2 μM achieves >80% reduction in SMAD phosphorylation within 60 minutes.

4. Animal Studies: Iron Metabolism Modulation and Inflammation

• For in vivo studies, administer Dorsomorphin via intraperitoneal injection at 10 mg/kg. Monitor hepatic hepcidin mRNA levels and serum iron after 24–48 hours. Expect significant reduction in hepcidin and increased circulating iron, supporting mechanistic studies of iron homeostasis.
• In models of obesity-related asthma, as highlighted in this recent study, AMPK modulation can influence M1 macrophage polarization and airway inflammation via the JAK2/STAT3 pathway. Dorsomorphin, as an AMPK inhibitor, provides a tool to dissect these immune-metabolic interfaces.

Advanced Applications and Comparative Advantages

Dorsomorphin’s unique profile as a dual AMPK and BMP/Smad pathway inhibitor empowers research across multiple frontiers:

• Autophagy Regulation and Metabolic Rewiring: Dorsomorphin enables precise control of autophagic proteolysis in cancer research and metabolic disease models. By inhibiting ACC phosphorylation and disrupting energy homeostasis, it reveals the intricacies of the AMPK signaling pathway, as detailed in this review (complementing the current focus on pathway specificity).
• Stem Cell Differentiation: In human embryonic stem cells, Dorsomorphin’s BMP/Smad inhibition fosters neural induction and self-renewal. This is supported by findings in recent articles that highlight its reproducibility and selectivity in stem cell workflows—a crucial advantage over less selective kinase inhibitors.
• Iron Metabolism Modulation: Dorsomorphin’s suppression of hepatic hepcidin and subsequent elevation of serum iron provide a robust model for studying iron regulation in health and disease, extending insights from osteoblast and Wnt signaling studies (extension of application scope).
• Cancer Research: By dissecting the metabolic dependencies of cancer cells and modulating autophagy, Dorsomorphin supports studies on therapeutic resistance and tumor microenvironment adaptation.

Compared to conventional AMPK inhibitors, Dorsomorphin (Compound C) offers:

• Superior selectivity for AMPK over related kinases, minimizing confounding off-target effects.
• Dual-action inhibition of BMP/Smad signaling, expanding its utility to developmental, regenerative, and iron metabolism research.
• Reproducibility and robustness, as consistently reported in APExBIO-supported studies and independent reviews.

Troubleshooting and Optimization Tips

Solubility and Handling

• Issue: Incomplete dissolution in DMSO.
  Solution: Apply gentle heating (37–40°C) and ultrasonic agitation for 5–10 minutes. Ensure use of high-grade, anhydrous DMSO to prevent precipitation.
• Issue: Decreased potency upon storage.
  Solution: Prepare fresh aliquots immediately before use. Store solid Dorsomorphin at -20°C; avoid repeated freeze-thaw cycles. Discard DMSO solutions after 24 hours.

Cell Viability and Off-Target Effects

• Issue: Cytotoxicity at higher concentrations (>40 μM).
  Solution: Titrate concentrations for each cell line. Begin with 4–10 μM and escalate only as needed. Verify with viability assays (e.g., MTT, trypan blue exclusion).
• Issue: Off-target kinase inhibition concerns.
  Solution: Dorsomorphin’s selectivity profile minimizes this risk, but include appropriate vehicle and kinase activity controls, especially when working in complex signaling environments.

Experimental Reproducibility

• Standardize cell passage number and confluency at time of treatment.
• Use freshly prepared Dorsomorphin solutions for each experiment to avoid degradation-related variability.
• For in vivo studies, monitor animal health and serum markers to distinguish compound effects from baseline physiological variation.

Future Outlook: Expanding the Frontier of Signaling Research

The versatility of Dorsomorphin (Compound C) continues to drive innovation across metabolic, autophagic, and differentiation research. As highlighted in the 2024 Inflammation study, precise modulation of the AMPK signaling pathway not only elucidates fundamental mechanisms—such as M1 macrophage polarization and airway inflammation in obesity-related asthma—but also identifies therapeutic targets via the JAK2/STAT3 axis. This positions Dorsomorphin as an indispensable tool for translational research, enabling targeted intervention strategies for metabolic and inflammatory diseases.

Emerging applications include:

• High-throughput screening for novel metabolic regulators using Dorsomorphin as a reference ATP-competitive AMPK inhibitor.
• Integration into CRISPR/Cas9 workflows for dissecting pathway redundancy and compensatory mechanisms in cancer and stem cell models.
• Expanded exploration of BMP/Smad signaling in regenerative medicine and iron metabolism disorders.

Supported by APExBIO’s rigorous quality standards and community-validated protocols, Dorsomorphin (Compound C) is poised to accelerate discoveries in the AMPK and BMP/Smad signaling landscapes. For additional protocol enhancements, comparative data, and troubleshooting guides, see the comprehensive overviews in these published resources—each offering nuanced perspectives on maximizing experimental impact.

In summary, Dorsomorphin (Compound C) is more than an inhibitor—it is a precision tool for unraveling cellular complexity, driving reproducible, high-impact research across disciplines.